The fixed-dose combination was first approved as Atripla in the United States in 2006 and in the European Union in late 2007. Numerous generic versions are also available. Branded Atripla will be ...

The first cross-class fixed-dose combination, Atripla, was developed by Gilead and Bristol–Myers Squibb (BMS), and launched in 2006 in the United States. This once-daily pill containing an NNRTI ...

University leaders, programs and businesses recognized as top contributors to Northern Nevada’s technological community at ...

The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, ...

From one big pill that only prolonged lives a few months, through the 20 pills a day years to modern combination therapies, ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

Standard ARV treatment for HIV infection is a regimen consisting of a combination of different drug classes. cART suppresses the proliferation of drug-resistant mutant strains by blocking a number ...

Tenofovir is available as tablets (300mg) and in fixed-dose combinations with emtricitabine (Truvada ®) and with emtricitabine plus efavirenz (Atripla ®); the latter combination was recently ...

Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Chris Schott from J.P. Morgan maintained a Buy rating on the stock ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...